Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APGN Apexigen (APGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Apexigen Stock (NASDAQ:APGN) 30 days 90 days 365 days Advanced Chart Ad Desko DigitalCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! Get Your FREE Gold Investor Kit NOW! Get Apexigen alerts:Sign Up Key Stats Today's Range$0.39▼$0.3950-Day Range$0.36▼$0.4452-Week Range$0.33▼$8.28VolumeN/AAverage Volume967,731 shsMarket Capitalization$9.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewApexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.Read More… Central Bank Abandons USD (Ad)You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! Get Your FREE Gold Investor Kit NOW! Receive APGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apexigen and its competitors with MarketBeat's FREE daily newsletter. Email Address APGN Stock News HeadlinesPyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition CompletedSeptember 7, 2023 | seekingalpha.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVID, CPRI, APGNAugust 11, 2023 | markets.businessinsider.comCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! November 22, 2024 | Desko Digital (Ad)Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual MeetingJune 3, 2023 | finance.yahoo.comEF Hutton Reiterates Apexigen (APGN) Hold RecommendationMay 27, 2023 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNL, RTL, APGNMay 24, 2023 | markets.businessinsider.comEF Hutton Maintains Apexigen (APGN) Buy RecommendationMay 17, 2023 | msn.comAPG SGA S.A.May 16, 2023 | wsj.comSee More Headlines APGN Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Apexigen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apexigen investors own include Sunworks (SUNW), Applied DNA Sciences (APDN), Ginkgo Bioworks (DNA), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Mullen Automotive (MULN) and Ambrx Biopharma (AMAM). Company Calendar Today11/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APGN CUSIPN/A CIK1814140 Webwww.apexigen.com Phone650-931-6236FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-614.82% Return on Assets-133.30% Debt Debt-to-Equity RatioN/A Current Ratio0.82 Quick Ratio0.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-4.28Miscellaneous Outstanding Shares24,862,000Free Float20,088,000Market Cap$9.57 million OptionableNot Optionable Beta3.60 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:APGN) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredBREAKING: NVDA loses $175 billion in 8 minutesIt's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, w...Chaikin Analytics | SponsoredThe AI Crash Begins November 30thMost AI stocks are doomed. I’m not an AI hater. AI will absolutely continue to be the most disruptive tech...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apexigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apexigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
